Wecofer Injection contains Iron Sucrose (20 mg/ml) and is indicated for the treatment of iron deficiency anemia, particularly in patients with chronic kidney disease (CKD) undergoing hemodialysis or those who are intolerant or unresponsive to oral iron therapy. This parenteral iron preparation provides a bioavailable source of iron necessary for hemoglobin synthesis and effective erythropoiesis. Wecofer Injection is administered intravenously, allowing for rapid replenishment of iron stores and correction of anemia. The formulation is designed to minimize the risk of free iron toxicity by delivering iron in a stable complex, thereby reducing oxidative stress and adverse reactions commonly associated with iron therapy. Dosage and administration should be individualized based on patient iron requirements, hemoglobin levels, and response to treatment, with careful monitoring to avoid iron overload. Common adverse effects may include transient hypotension, nausea, headache, and injection site reactions. Hypersensitivity reactions, although rare, require immediate medical attention. Wecofer Injection should be used with caution in patients with active infections or iron overload conditions. Proper patient evaluation and adherence to recommended dosing protocols are essential to optimize therapeutic outcomes and ensure patient safety.